Opinion|Videos|September 27, 2024
Frontline Treatment and Sequencing Therapy
Panelists discuss how their institutions approach frontline treatment for transplant-eligible multiple myeloma patients, typically using a combination of novel agents like proteasome inhibitors and immunomodulatory drugs, followed by autologous stem cell transplantation and maintenance therapy, while considering factors such as patient characteristics and treatment response to guide therapy sequencing.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What does your institution use for frontline treatment and how do you sequence therapy for patients who are transplant-eligible?
Advertisement
Related to this article
September highlights Blood Cancer Awareness Month, focusing on education, early diagnosis, and support for multiple myeloma, lymphoma, and leukemia patients.
The data support GPRC5D-directed CAR T-cell therapy as a potential option following prior BCMA-targeted treatment.
Advertisement
Advertisement
Trending on Pharmacy Times
1
How Pharmacists Overcome PCSK9 Inhibitor Access Barriers
2
From Reactive to Proactive: AI's Role in Modern Pharmacy Safety
3
Trial Ended Early When Venetoclax Plus DA-EPOCH-R Did Not Improve Outcomes in Double-Hit Lymphoma
4
Pharmacists' Role as Ketone Monitoring Reaches Clinics
5